Abstract
Peptide growth factors are a fascinating group of molecules with diverse effects. Recent developments have allowed us to gain a much greater insight into their pathophysiological functions. In addition, the development of recombinant peptide technology, monoclonal antibody production and both artificial small molecule receptor agonists and inhibitors now allows us to use these factors for the treatment of multiple conditions including gastrointestinal malignancy (particularly colonic carcinoma), short bowel syndrome (where factors such as growth hormone, epidermal growth factor and glucagons-like peptide 2 show particular promise), and inflammatory bowel disease.
| Original language | English |
|---|---|
| Pages (from-to) | 567-571 |
| Number of pages | 5 |
| Journal | Current Opinion in Pharmacology |
| Volume | 4 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Dec 2004 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Growth factors and trefoil peptides in gastrointestinal health and disease'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver